Due to a measles case in the community, please call before coming to Seattle Children’s if you or your child has potential measles symptoms.

Current Research Studies

A Phase 3, Prospective, Open-Label, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Paricalcitol Oral Solution for the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects Ages 0 to 9 Years with Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis

Abbvie Zemplar 0-9

What is the goal of the study?

THis Phase 3 multi center study will evaluate the safety, efficacy and pharmacokinetics of paricalcitol oral solution for the treatment of secondary hyperparathyroidism (SHPT) in pediatric subjects 0 to 9 years of age with stage 5 chronic kidney disease (CKD), receiving peritoneal dialysis (PD) or hemodialysis (HD).

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Joseph Flynn
Study Team Member: Megan Kelton-Rehkopf, Megan.Kelton@seattlechildrens.org

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.